Swedish pharmaceutical company Newbury Pharmaceuticals AB (STO:NEWBRY) said on Wednesday that it has received marketing authorisation for Bosutinib Newbury in Norway.

This marks the first step in a Scandinavian registration process, with approvals expected in Sweden and Denmark soon.

Bosutinib Newbury is a generic version of Bosulif, indicated for the treatment of adult patients with Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML).

This approval provides access to an important treatment option for patients in the Scandinavian market, estimated to be worth EUR5.5m annually.